Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

11:45
DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, has announced that its lead program, DBI-001, met its primary safety endpoints, with no application site reactions and no adverse events, in a 12...

10:33
Tishcon Corp., a leading manufacturer and marketer of vitamins, dietary and herbal supplements has announced that the results of an independent study on the efficacy of the company's Freedom Softgels® in treating hypertension and chronic inflammation...

10:25
On behalf of the more than 5 million Americans living with Alzheimer's and their family members, the Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based...

10:00
HighTide Therapeutics Inc. ("HighTide"), a clinical-stage biopharmaceutical company, today announced that the last patient has been enrolled in A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With...

09:21
4G Clinical today announced its recognition as the Bio Supply Management Alliance (BSMA) Supply Chain Management Excellence and Innovation Award 2019 recipient for its utilization of natural language processing (NLP) to turn study parameters into...

09:15
Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announces that BIOC11 eradicated 99% of the Nontuberculous Mycobacteria (NTM) in an in vivo animal model of infection; this data will be presented at the National Cystic Fibrosis Conference to...

09:00
Children's National Research Institute (CNRI), the research arm of the nation's No. 6 ranked children's hospital is rolling out the TriNetX platform to investigators at Children's National Hospital and taking the lead in establishing a research...

09:00
MedHub develops decision-support systems for cardiologists that leverage Artificial Intelligence (AI) to guide cardiologists during the diagnostic cardiac angiography process. The fully automated system, named AutocathFFR, detects stenoses...

08:30
Actify, formerly Actify Neurotherapies, a transformative and innovative mental health care provider, today announced the expansion of its services aimed to improve the treatment experience and lives of patients living with major depressive disorder...

08:30
There is much research activity in the acute myeloid leukemia (AML) the sector. The American Cancer Society's (ACS) estimates for leukemia in the United States for 2019 predict that there will be 61,780 new cases of leukemia (all kinds) and 22,840...

08:15
Trovagene, Inc. , a clinical-stage, Precision Cancer Medicinetm oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today announced data...

08:11
GT Biopharma, Inc. (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKEtm) platform, announced today that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the...

08:07
BioGX B.V., the European subsidiary of Birmingham, Alabama based BioGX, announced it has received CE-IVD marking for its new Flu A, Flu B, RSV A/B automated test. The new test significantly enhances the strain coverage and detection sensitivity and...

08:03
TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, and Limbix, a company improving mental healthcare through mobile apps and virtual reality (VR), have partnered to plan...

08:00
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced on behalf of the global strategic alliance with...

08:00
Titan Pharmaceuticals, Inc. today announced that it has two poster presentations on Probuphine (buprenorphine) implant, Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients, at the 10th American Conference...

07:30
BridgeBio Pharma, Inc. today announced that promising preclinical data from two of its gene therapy-focused subsidiaries ? Adrenas Therapeutics and Aspa Therapeutics ? will be presented at the European Society of Gene and Cell Therapy (ESGCT)...

07:30
Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in vivo data on the company's novel...

07:30
Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the expansion of Annamycin production commitments in...

07:11
Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360? viscodilation of Schlemm's Canal using...

07:00
Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of...

07:00
Provention Bio, Inc. , a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced top-line results from its randomized, placebo-controlled Phase 2a PRINCE clinical trial evaluating...

05:44
The world-class journal Cell, an international high-impact journal, published the article "Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma in China." The research was jointly conducted and published by the teams of...

03:00
Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics,  presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy,...

02:46
Q-linea AB (publ) , today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second half of 2020. This is a postponement as the trials previously were expected to...


21 october 2019

19:00
Persistent psychological stress, which is widely recognized as a consequence of vision loss, is also a major contributor to its development and progression, according to a study published in the EPMA Journal, the official journal of the European...

18:01
The results of a major study across 195 countries, presented today at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both increased by 10% between 1990 and 2017. The Global...

16:05
Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that results of EMMINENCE, its Phase 2b clinical...

16:00
Theravance Biopharma, Inc. ("Theravance Biopharma") and Mylan N.V.  ("Mylan") today announced that data from studies of YUPELRI® (revefenacin) inhalation solution will be presented at CHEST 2019, the annual meeting of the American College of Chest...

11:23
Systematic depression screening for survivors of acute coronary syndromes did not demonstrate patient benefit, according to The Feinstein Institutes for Medical Research Professor and Senior Vice President Karina W. Davidson, PhD, MASc. The findings,...

10:15
Mallinckrodt plc , a global biopharmaceutical company, today announced it will present results from its pivotal Phase 3 CONFIRM study in a late-breaker session on Monday, Nov. 11 at 3:30 pm ET during The Liver Meeting® 2019, the annual meeting of the...

10:12
DURECT Corporation announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic hepatitis (AH) have been selected for an oral presentation as part of the late-breaking session of The Liver...

10:00
On the Advocate Lutheran General Hospital campus, Park Ridge, Illinois, Advocate Medical Group Adult Down Syndrome Center researchers are enrolling adults with Down Syndrome who are older than 25 in the Longitudinal Investigation for Enhancing Down...

09:30
Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has entered into an agreement with Aptar Pharma...

09:00
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announces new data evaluating initial combination therapy with OPSUMIT® (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial...

09:00
The Massachusetts General Hospital (MGH) Down Syndrome Program was the first approved research site in the first clinical trial in the Down Syndrome ? Clinical Trials Network (DS-CTN). MGH is enrolling adults with Down Syndrome over the age of 25 in...

09:00
Eiger BioPharmaceuticals, Inc. , focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare diseases, today announced that a late-breaker oral presentation has been granted for interim end...

08:31
LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses...

08:17
Amygdala Neurosciences (a private company) has been awarded up to $1.35 million NIH grant support for the project titled "26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other...

08:12
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study. The data demonstrated that the majority of adult patients with moderately to severely active...

08:00
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today...

08:00
Soliton, Inc., ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announces it will host a...

08:00
Sophiris Bio Inc.  (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced...

07:00
Alkermes plc today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230, Alkermes' immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein...

04:20
As health care services continue to be under immense amounts of pressure, technological advancements are the way forward, say AHSN. The NHS has been around for over 70 years, but some say its traditional practises need to move with the times. "A...

02:00
Perflow Medical, a private, Israeli-based innovator of solutions for neurovascular treatment, today announced they have received CE Mark approval for the Cascadetm Agile Non-Occlusive Remodeling Net (Cascade Agile). Expanding the Cascade product...


20 october 2019

20:00
Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today...


19 october 2019

04:30
-- New advancements to our technologies designed to further improve blood product inventory management and optimize the blood supply chain to be demonstrated at the Biolog-id booth (#508) -- Biolog-id to host industry workshop featuring a panel...


18 october 2019

11:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application...

09:00
The National Institutes of Health (NIH) has awarded Matthew David Taylor, MD, instructor in the Institute of Molecular Medicine at The Feinstein Institutes for Medical Research, with a four-year, $781,920 grant for his efforts to determine whether...

1 2 3 4 5 6 7 8 9 10